Medicine To Market News’ Post

🌍 The global #pharma market is projected to reach a staggering $1.7 trillion by 2030, according to Evaluate Ltd’s 2024 @World Preview Report. With an expected growth rate of 7.7% through the decade, the pharmaceutical industry is poised for transformative developments. #Obesity drugs are forecasted to lead this surge, with more potent compounds, combinations, and oral formulations set to make a significant impact. Exciting advancements in new modalities and technologies are also on the horizon, including #ntibody drug conjugates (#ADCs), multi-specific #antibodies, #RNA-based therapies, gene/cell therapies, and #radiopharmaceuticals. While patent expiries remain a challenge, the dynamic landscape of mergers and acquisitions is helping to address these issues. With $124 billion in pharma acquisitions in 2023, this trend shows no signs of slowing down. Pharma cash-piles and expiry pressures will likely drive even more deals, as the industry adapts to new technologies and legislative changes like the US Inflation Reduction Act. Connect, Repost & Follow for more info on the #pharmaceutical industry 🌍 #pharma #pharmaindustry #europe #pharmaceuticalindustry #healthcare

Discover the event's pivotal moments and our esteemed partners M R Sanghavi & Co., Rockwell Automation, MP Biomedicals, PharmNXT Biotech, Ami Polymer Pvt. Ltd., Kevin Technologies, Omega Scientific Instruments Pvt.Ltd.. Secure your spot now for the 4th Edition of the India Biopharma Leaders Conclave, proudly presented by M R Sanghavi & Co., powered by Rockwell Automation, and hosted by BlueTech Media™. Together, we're set to embark on a journey to explore "New Horizons in Biopharma, Biosimilars, & Biologics"! 🚀 . Date: 13th & 14th June, 2024, Hyderabad To Register for the event click https://lnkd.in/d2T9iruW . This year's theme promises a deep dive into the latest advancements shaping the biopharmaceutical landscape, with a spotlight on the exciting realms of biosimilars and biologics. With renowned speakers and eminent leaders from around the globe, this event is set to be a beacon of knowledge and innovation. . Why Attend: 🔍 Gain valuable insights into industry evolution, regulatory changes, and compliance challenges. 🤝 Expand your professional network by connecting with industry peers and potential collaborators. 💡 Discover cutting-edge products, services, and technologies driving biopharma innovation. 🔄 Engage in meaningful discussions to shape the future trajectory of the industry. 🔬 Explore challenges and opportunities, from regulatory hurdles to ethical considerations. . Event Highlights: 🎤 40+ Speakers 🤝 200+ Delegates 🤝 4+ Associations 📰 4+ Media Partners 🤝 15+ Partners . Key Topics Include: 🔬 The future and challenges of biosimilars 🔬 Success rates and challenges in biosimilar R&D 🔬 Quality, safety, and efficacy standards in biosimilars 🔬 Future of cell and gene therapy manufacturing 🔬 Emerging trends in quality assurance for biologics 🔬 Digitalized supply chains in biopharma 🔬 The crucial role of a digital backbone in the industry 🔬 Advances and barriers in CAR-T cell therapies Don't miss this opportunity to be at the forefront of biopharmaceutical innovation! . #Bluetechmedia #IndiaBiopharmaLeadersConclave #pharmaevents #pharmaceutical #Corporate #PharmaEvents #PharmaConferences #PharmaConclave #PharmaLeaders #BlueTechMedia #BiopharmaLeaders #Innovation #Biosimilars #Biologics #IndustryInsights

BridGene Biosciences, Inc. co-founders Dr. Ping Cao and Irene Yuan write about chemoproteomics and the challenges of drugging undruggable targets in the January-February issue of Drug Development & Delivery magazine. #undruggabletargets #chemoproteomics DRUG DISCOVERY - Overcoming Traditional Challenges: Innovative Chemoproteomics Strategies to Revolutionize Drug Discovery (drug-dev.com)

🌐 Pfizer’s Q3 Update: Steady Growth & Strategic Deals Amid Industry Shifts Pfizer’s Q3 earnings have shown resilience despite the evolving challenges in the pharmaceutical industry. With ongoing partnerships and strategic acquisitions, they’re strengthening their pipeline, especially in areas like oncology and rare diseases. Notable collaborations include alliances that position Pfizer at the forefront of innovation, ensuring they stay competitive in a post-pandemic landscape. Looking ahead, Pfizer’s moves underscore a broader trend of pharma giants adapting quickly through targeted investments. These changes point to a future where agility and collaboration are essential to drive meaningful impact. https://lnkd.in/gzAKsZyH #Pharma #Innovation #Biotech #Partnerships

𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗖𝗗𝗠𝗢 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟮. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The report offers an overview of the Biologics CDMO Services industry chain development, assessing the market status of both Small and Medium-sized Businesses (SMBs) and Large Companies in sectors such as Cell and Gene Therapies, and Antibodies. It delves into key enterprises in both developed and developing markets, analyzing cutting-edge technology, patents, hot applications, and market trends within Biologics CDMO Services. Regionally, North America and Europe are experiencing steady growth, propelled by government initiatives and heightened consumer awareness. Meanwhile, Asia-Pacific, particularly China, leads the global Biologics CDMO Services market due to robust domestic demand, supportive policies, and a strong manufacturing base. The report presents a comprehensive understanding of the Biologics CDMO Services market, providing insights into industry dynamics, trends, challenges, and opportunities for stakeholders. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗖𝗗𝗠𝗢 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁.𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dufsCMSd *𝗕𝘆 𝗧𝘆𝗽𝗲: Cell and Gene Therapies,  Antibodies,  Vaccines,  Other *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: SMBs,  Large Companies *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Lonza,  Catalent,  Samsung Biologics,  FUJIFILM Diosynth Biotechnologies,  Boehringer Ingelheim,  WuXi AppTech,  Recipharm,  Thermo Fisher Scientific,  AGC Biologics,  Rentschler Biopharma,  KBI Biopharma,  Siegfried,  Aenova Group,  GenScript,  ProBioGen #biologicscdmo #biopharmaceuticals #contractmanufacturing #pharmaceuticals #cdmo #biotechnology #bioprocessing #drugdevelopment #biomanufacturing #contractdevelopment #outsourcing #healthcareindustry #pharmaservices #biotechindustry #life sciences #drugmanufacturing #contractresearch #drugdiscovery #biologicsproduction #clinicalresearch #healthcareservices

Today’s #pharmaceutical landscape is evolving fast. As industry shifts towards #personalizedmedicine and #artificialintelligence take hold, forward-thinking #drugdevelopers need to embrace customization and flexibility in order to remain competitive. In a new blog by Anil Kane, Ph.D., MBA, Executive Director, Global Head of Technical and Scientific Affairs at Thermo Fisher Scientific, he breaks down several topics of conversation from #CPHI2023, specifically covering three trends that will impact #pharma companies in 2024, including: - Pharma companies are turning to flexible manufacturing in response to changing regulatory and market requirements - Pharma companies are embracing digital enablement to efficiently increase productivity and meet patient needs - In the evolving biotechnology and pharmaceutical landscape, #CDMO partners must deliver transformational value Read the blog to learn more about Anil’s predictions for the new year and beyond: http://spr.ly/6043T2PRS

🌍 Unveil the Future of Drug Discovery Technologies! 🧬 Our latest market report highlights the booming drug discovery technologies market, projected to grow from $111.9 billion in 2024 to an impressive $197.0 billion by 2029, at a CAGR of 12.0%. As pharmaceutical innovation accelerates, advanced technologies like AI-driven drug design, high-throughput screening, and bioinformatics are revolutionizing how new treatments are discovered. These cutting-edge technologies are speeding up drug development and improving precision in targeting diseases. From cancer to neurological disorders, drug discovery advancements are enabling more effective treatments, bringing hope to millions. Our comprehensive report explores key trends, growth drivers, and market forecasts, offering a deep dive into the future of healthcare and biopharmaceutical innovation. Stay ahead with actionable insights into this rapidly evolving landscape! https://bit.ly/3XEVcUX #DrugDiscovery #PharmaInnovation #AIinHealthcare #BiotechTrends #HealthcareFuture #DrugDevelopment #MedicalResearch #Pharmaceuticals #MarketGrowth #Biotechnology

Agilent Technologies, which has made its mark selling equipment and services to drugmakers, will get a swift boost to its contract manufacturing muscle for oligonucleotides and CRISPR therapeutics, the company said Monday.... ...Agilent has revealed that it’s signed a definitive agreement to acquire BIOVECTRA for $925 million through a mix of cash and debt financing. The deal, which must secure regulatory approvals, is expected to close before 2025, Agilent said in a press release.... Once the deal closes, Biovectra will join the fold as part of Agilent Diagnostics & Genomics Solutions Group, Agilent added... #CRISPR #geneediting #genetherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #genomics #diagnositics #therapeutics #lifescience #lifesciences #Biotech #biotechnology #CDMO #manufacturing #925m #biologics #commercialmanufacturing #clinicaltrials #plasmidNA #pDNA #mRNA #lipidnanoparticles #antibodydrugconjugates #ADCs #acquisition #mergersandacquisitions #financing #contractmanufacturing

【NEWS UPDATE】🚀 Eli Lilly Partners with AI Innovator Genetic Leap to Transform Drug Development! 🤖 https://lnkd.in/gHqtxpnJ In a groundbreaking move for the pharmaceutical industry, Eli Lilly has entered into a research collaboration valued at up to $409 million with Genetic Leap, an emerging AI-driven drug developer. This partnership highlights the exciting potential of combining advanced technology with biomedical research! 🌟 Under this collaboration, Genetic Leap will leverage its cutting-edge AI and machine learning capabilities to discover and develop new RNA-based therapies. Since its inception in 2017, Genetic Leap has been at the forefront of integrating AI with biotechnology, attracting significant attention and partnerships with leading pharmaceutical companies, including Eli Lilly. 💡 This collaboration follows Eli Lilly's strategic acquisition of Dice Therapeutics for $2.4 billion, further strengthening its immunology portfolio. The trend of pharmaceutical giants acquiring biotech firms focused on innovative therapies continues, as seen with Merck's recent $10.8 billion acquisition of Prometheus Biosciences. 📈 Eli Lilly, established in 1876, has a rich legacy in the pharmaceutical sector, from pioneering insulin production to developing essential treatments like Prozac and Cymbalta. This latest partnership marks another significant step in Eli Lilly's commitment to advancing global health through innovation. 🌍 👉 Stay tuned for more updates on this exciting collaboration! #EliLilly #GeneticLeap #PharmaceuticalInnovation #ArtificialIntelligence #DrugDevelopment #Biotechnology #RNAtherapies #HealthTech #Immunology #Collaboration

In this week's pharmaceutical industry news, significant investments, strategic partnerships, and innovative studies come to the fore. We have compiled the most prominent developments for you. 👇 Enjoy your reading! ✅ #Sanofi is planning to construct a new insulin production facility at its BioCampus in Frankfurt Höchst, Germany. https://lnkd.in/dk-6RN2B ✅ Data insights from GlobalData reported that in 2023, major players in the biopharma sector generated “significant” revenue growth from obesity drugs. https://lnkd.in/e5TfvY3V ✅ Researchers from King’s College London have developed a new artificial intelligence (AI) brain imaging model in collaboration with University College London (UCL) which is realistic and accurate enough to use in medical research. https://lnkd.in/dcXg2z_R   ✅ Biotech startup #Meddenovo Drug Design announced the successful completion of an investment round led by ACT Venture Partners. The investment will be used to accelerate research and development and enhance Meddenovo's AI-focused platforms. https://lnkd.in/dBzQEB6k ✅ #Roche’s Genentech and Sangamo enter neurodegenerative disease partnership worth over $1.9bn. https://lnkd.in/ep5Yea3M ✅ #BoehringerIngelheim expands immuno-oncology pipeline with $1.3bn Nerio acquisition. https://lnkd.in/di5ZcFCd   ✅ #Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn. https://lnkd.in/dRfjsanK   ✅ #EliLilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue. https://lnkd.in/dPYJvVCG #pharmanews #strategyconsulting #pharmaceuticals #fitminds